10779/rcsi.10765331.v1 Emily J. Ryan Emily J. Ryan Alan J. Ryan Alan J. Ryan Arlyng Gonzalez Vazquez Arlyng Gonzalez Vazquez Anahí Philippart Anahí Philippart Francesca E. Ciraldo Francesca E. Ciraldo Christopher Hobbs Christopher Hobbs Valeria Nicolosi Valeria Nicolosi Aldo R. Boccaccini Aldo R. Boccaccini Cathal Kearney Cathal Kearney Fergal J. O'Brien Fergal J. O'Brien Collagen scaffolds functionalised with copper-eluting bioactive glass reduce infection and enhance osteogenesis and angiogenesis both in vitro and in vivo. Royal College of Surgeons in Ireland 2019 Osteomyelitis Copper Bioactive glass Antibacterial Osteogenesis Angiogenesis. Anatomy 2019-11-23 11:40:19 Journal contribution https://repository.rcsi.com/articles/journal_contribution/Collagen_scaffolds_functionalised_with_copper-eluting_bioactive_glass_reduce_infection_and_enhance_osteogenesis_and_angiogenesis_both_in_vitro_and_in_vivo_/10765331 <p>The bone infection osteomyelitis (typically by Staphylococcus aureus) usually requires a multistep procedure of surgical debridement, long-term systemic high-dose antibiotics, and - for larger defects - bone grafting. This, combined with the alarming rise in antibiotic resistance, necessitates development of alternative approaches. Herein, we describe a one-step treatment for osteomyelitis that combines local, controlled release of non-antibiotic antibacterials with a regenerative collagen-based scaffold. To maximise efficacy, we utilised bioactive glass, an established osteoconductive material with immense capacity for bone repair, as a delivery platform for copper ions (proven antibacterial, angiogenic, and osteogenic properties). Multifunctional collagen-copper-doped bioactive glass scaffolds (CuBG-CS) were fabricated with favourable microarchitectural and mechanical properties (up to 1.9-fold increase in compressive modulus over CS) within the ideal range for bone tissue engineering. Scaffolds demonstrated antibacterial activity against Staphylococcus aureus (up to 66% inhibition) whilst also enhancing osteogenesis (up to 3.6-fold increase in calcium deposition) and angiogenesis in vitro. Most significantly, when assessed in a chick embryo in vivo model, CuBG-CS not only demonstrated biocompatibility, but also a significant angiogenic and osteogenic response, consistent with in vitro studies. Collectively, these results indicate that the CuBG-CS developed here show potential as a one-step osteomyelitis treatment: reducing infection, whilst enhancing bone healing.</p>